Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
oregovomab · 1 trial · 1 indication
Change from baseline CA125 ELISPOT assay after stimulation with oregovomab (MAb-B43.13 against CA125) measured at approximately 12 weeks and 25 weeks after the start of first-line chemotherapy
| Arm | Type | Description |
|---|---|---|
| carboplatin & paclitaxel | ACTIVE_COMPARATOR | first-line chemotherapy for ovarian cancer |
| carboplatin & paclitaxel & oregovomab | EXPERIMENTAL | first-line chemotherapy for ovarian cancer plus oregovomab |
| Name | Type | Description |
|---|---|---|
| Carboplatin | DRUG | carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\]) |
| Paclitaxel | DRUG | Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\]) |
| oregovomab | BIOLOGICAL | oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle). |
Inclusion Criteria: * have newly diagnosed epithelial adenocarcinoma of ovarian, tubal or peritoneal origin and French Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) Stage III/IV disease. * have preoperative CA125 levels \> 50 U/mL * have optimal cytoreduction (RT\<1) * be anticip...
Oregovomab is a monoclonal antibody being studied for the treatment of ovarian neoplasms, specifically advanced ovarian cancer. It is currently in Phase 2 clinical development and is intended for use in combination with chemotherapy for this patient population.
Oregovomab is a monoclonal antibody that targets CA-125, a tumor-associated antigen commonly expressed in ovarian cancer. By binding to CA-125, it is designed to elicit an immune response against cancer cells expressing this antigen.
Oregovomab is being developed by Quest Diagnostics Inc., a company publicly traded under the ticker symbol DGX. The company is conducting clinical trials to evaluate the drug's effectiveness in treating advanced ovarian cancer.
Oregovomab is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 2 trial has been completed to assess its efficacy in combination with chemotherapy for advanced ovarian cancer.
Oregovomab has been studied in one clinical trial, NCT01616303, titled 'A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer.' This Phase 2 trial enrolled 97 female participants aged 18 years and older in the United States and has been completed.
Oregovomab is also known by its developmental code name. It is a monoclonal antibody that specifically targets CA-125, and it is being investigated as a potential treatment for ovarian cancer. No other alternative names have been reported for this drug.